Compositions for the treatment of addiction, psychiatric disorders, and neurodegenerative disease
US9078886B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jun 16, 2011 |
| Grant date | Jul 14, 2015 |
| Priority date | — |
| Expiry date | Jun 16, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention features, inter alia, pharmaceutically acceptable compositions that include metyrapol as the sole pharmaceutically active agent; compositions that include metyrapol and at least one additional pharmaceutically active agent; compositions in which the agent targeting the HPA axis is, itself, new or modified (e.g., a bi-specific antibody designed to traverse the blood-brain barrier or a known compound redesigned by, for example, conjugation to a substance that traverses the blood-brain barrier); and compositions in which the agent targeting the HPA axis is newly formulated in such a way that it fails to significantly inhibit cortisol production in the adrenal gland. For example, the composition can be formulated to include a dosage that is too low to reduce plasma cortisol levels or formulated to preferentially affect the skin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.